For the Inventor, By the Inventor

Enter assignee name

Basel, Switzerland

Novartis Pharma Ag

USPTO Granted Patents = 36

% Expired Patents = 36.1

CIPO Patents = 2

EPO Patents = 14

Trademarks = 14

Forward Citations = 480

Loading Chart...

Loading Chart...

127 inventors (with patents filed for the assignee):

James B Fink (3 out of 25 patents)

Adrian Edward Smith (3 out of 32 patents)

Thomas K Brewer (3 out of 11 patents)

4. Derrick J Parks (3 out of 12 patents)

5. Luis A Dellamary (2 out of 77 patents)

6. Margarita Gekkieva (2 out of 4 patents)

7. John Sylvester Power (2 out of 28 patents)

8. Jon David Tuckwell (2 out of 6 patents)

9. Alessandro M Vannucchi (2 out of 2 patents)

10. Costanza Bogani (2 out of 2 patents)

11. Thomas E Tarara (2 out of 38 patents)

12. Yigal Paul Goldberg (2 out of 14 patents)

13. Kyle A Naydo (2 out of 14 patents)

14. Michael D Winther (2 out of 16 patents)

15. Robert M Platz (2 out of 40 patents)

Core Competencies:

IL-17 Antibodies

Aerosolization

Diabetic Retinopathy

Chimeric Antigen Receptors

JAK Inhibitors

STING Activity

Beta-L-2'-Deoxythymidine

Therapeutic Agents

Hydrophobic Components

Medicament Delivery

Spray Drying

Mass Sensing

36 patents: Sort by Forward Citations

1. 12741024 - PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES (2026-09-22),

2. 12735502 - IMMUNOGLOBULIN VARIANTS (2026-09-15),

3. 12703762 - REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF (2026-08-11),

4. 12702711 - PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES (2026-08-11),

5. 12649781 - METHODS FOR TREATING DIABETIC RETINOPATHY USING BROLUCIZUMAB (2026-06-09),

6. 12630604 - METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS (2026-05-19),

7. 12503436 - Compounds and compositions for treating conditions associated with STING activity (2025-12-23),

8. 10762980 - Computer-implemented methods of determining protein viscosity (2020-09-01),

9. 10035850 - Methods for treating neovascular age-related macular degeneration (2018-07-31),

10. 9993480 - mTOR/JAK inhibitor combination therapy (2018-06-12),

11. 9458240 - Anti-BAFFR antibody formulations (2016-10-04),

12. 9358229 - JAK PI3K/mTOR combination therapy (2016-06-07),

13. 8869794 - Aerosolization apparatus with capsule puncturing member (2014-10-28),

14. 8802149 - Systems and processes for spray drying hydrophobic and hydrophilic components (2014-08-12),

15. 8336545 - Methods and systems for operating an aerosol generator (2012-12-25),

Company Overview

Novartis Pharma AG, headquartered in Basel, Switzerland, is a global healthcare company focused on the research, development, manufacturing, and marketing of innovative pharmaceuticals. The organization specializes in a wide range of therapeutic areas, including oncology, cardiology, immunology, and neuroscience, aiming to address significant unmet medical needs. With a commitment to advancing healthcare through science, Novartis leverages cutting-edge technologies and research to deliver transformative treatments to patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

36 Patents

#16 in Basel

#387 in Switzerland

#18,730 in the World

Basel, Switzerland

Novartis Pharma Ag

Forward Citations = 480

127 inventors:

James B Fink (3 out of 25 patents)

Adrian Edward Smith (3 out of 32 patents)

Thomas K Brewer (3 out of 11 patents)

4. Derrick J Parks (3 out of 12 patents)

5. Luis A Dellamary (2 out of 77 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novartis Pharma Ag. Retrieved from https://idiyas.com/company/novartis-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…